Thus, in addition to the G-CSF double treatment schedule (REAC, n = 8), we included one latent infection cohort which did not receive the second hG-CSF daily administrations between weeks 24 and 25 (INF, n = 8) (Figure 2A). Here, CSF3 is linked to disease arising from reactivation of latent virus.